Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

A new coronavirus associated with human respiratory disease in China

Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983 · see citing works

Structural basis of receptor recognition by SARS-CoV-2

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · see citing works

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · see citing works

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · see citing works

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · see citing works

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · see citing works

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,908 · see citing works

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642 · see citing works

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420 · see citing works

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308 · see citing works

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282 · see citing works

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253 · see citing works

Viral Mutation Rates

Sanjuán, R., Nebot, M. R., Chirico, N., Mansky, L. M., & Belshaw, R. D. (2010) · Journal of Virology · doi:10.1128/jvi.00694-10 · Cited by 1,247 · see citing works

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · see citing works

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140 · see citing works

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Ke, Z., Otón, J., Qu, K., Cortese, M., Žíla, V., McKeane, L., Nakane, T., Zivanov, J., Neufeldt, C. J., Cerikan, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2665-2 · Cited by 1,113 · see citing works

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Munnink, B. B. O., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Münger, E., Molenkamp, R., van der Spek, A. N., Tolsma, P., Rietveld, A., Brouwer, M., et al. (2020) · Science · doi:10.1126/science.abe5901 · Cited by 1,087 · see citing works

Potently neutralizing and protective human antibodies against SARS-CoV-2

Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041 · see citing works

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016 · see citing works

Viral quasispecies evolution

Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009 · see citing works

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Zang, R., Castro, M. F. G., McCune, B. T., Zeng, Q., Rothlauf, P. W., Sonnek, N. M., Liu, Z., Brulois, K. F., Wang, X., Greenberg, H. B., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc3582 · Cited by 982 · see citing works

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 955 · see citing works

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognitionPreprint

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R. T., Crawford, K. H. D., et al. (2020) · bioRxiv · doi:10.1101/2020.09.10.292078 · Cited by 948 · see citing works

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762 · see citing works

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2708-8 · Cited by 675 · see citing works

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Chan, K. K., Dorosky, D. E., Sharma, P. A., Abbasi, S. A., Dye, J. M., Kranz, D. M., Herbert, A. S., & Procko, E. (2020) · Science · doi:10.1126/science.abc0870 · Cited by 613 · see citing works

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., Ni, M., Wei, Y., Mohammadi, K., Musser, B., et al. (2020) · Science · doi:10.1126/science.abe2402 · Cited by 517 · see citing works

Transmission of SARS-CoV-2 in Domestic Cats

Halfmann, P., Hatta, M., Chiba, S., Maemura, T., Fan, S., Takeda, M., Kinoshita, N., Hattori, S.-I., Sakai‐Tagawa, Y., Iwatsuki‐Horimoto, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2013400 · Cited by 465 · see citing works

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

ACTIV-3/TICO LY-CoV555 Study Group (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2033130 · Cited by 433 · see citing works

Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics

Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 428 · see citing works

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410 · see citing works

Broadly protective human antibodies that target the active site of influenza virus neuraminidase

Stadlbauer, D., Zhu, X., McMahon, M., Turner, J. S., Wohlbold, T. J., Schmitz, A. J., Strohmeier, S., Yu, W., Nachbagauer, R., Mudd, P. A., et al. (2019) · Science · doi:10.1126/science.aay0678 · Cited by 261 · see citing works

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Du, S., Cao, Y., Zhu, Q., Yü, P., Qi, F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.035 · Cited by 238 · see citing works

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181 · see citing works

Coronaviruses as DNA Wannabes: A New Model for the Regulation of RNA Virus Replication Fidelity

Smith, E. C., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003760 · Cited by 107 · see citing works

Mapping the Evolutionary Potential of RNA Viruses

Dolan, P., Whitfield, Z. J., & Andino, R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.03.012 · Cited by 91 · see citing works

Structures, conformations and distributions of SARS-CoV-2 spike protein trimers on intact virionsPreprint

Ke, Z., Otón, J., Qu, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.27.174979 · Cited by 63 · see citing works

Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312.sa2 · Cited by 53 · see citing works

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2Preprint

Case, J. B., Rothlauf, P. W., Chen, R. E., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3606354 · Cited by 19 · see citing works

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178 · see citing works

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · see citing works

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901 · see citing works

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697 · see citing works

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651 · see citing works

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557 · see citing works

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651 · see citing works

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.042 · Cited by 341 · see citing works

The variant gambit: COVID-19’s next move

Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328 · see citing works

Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants

de Puig, H., Lee, R. A., Najjar, D., Tan, X. J., Soenksen, L. R., Angenent-Mari, N. M., Donghia, N. M., Weckman, N. E., Ory, A. L. H., Ng, C. F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2944 · Cited by 326 · see citing works

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsPreprint

Planas, D., Veyer, D. L., Baidaliuk, A., Staropoli, I., Guivel‐Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.26.445838 · Cited by 272 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

Eguia, R., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D. (2020) · doi:10.1101/2020.12.17.423313 · Cited by 258 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

(2021) · doi:10.1371/journal.ppat.1009453 · Cited by 258 · see citing works

Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation

Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651 · see citing works

Phase separation in immune signalling

Xiao, Q., McAtee, C. K., & Su, X. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00572-5 · Cited by 232 · see citing works

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

Munnink, B. B. O., Worp, N., Nieuwenhuijse, D. F., Sikkema, R. S., Haagmans, B. L., Fouchier, R. A. M., & Koopmans, M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01472-w · Cited by 229 · see citing works

Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?

Vasireddy, D., Vanaparthy, R., Mohan, G., Malayala, S. V., & Atluri, P. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4518 · Cited by 197 · see citing works

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

Laffeber, C., de Koning, K., Kanaar, R., & Lebbink, J. H. G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167058 · Cited by 190 · see citing works

The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape

Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751778 · Cited by 192 · see citing works

Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series

Truong, T., Ryutov, A., Pandey, U., Yee, R., Goldberg, L., Bhojwani, D., Aguayo-Hiraldo, P. I., Pinsky, B. A., Pekosz, A. S., Shen, L., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103355 · Cited by 183 · see citing works

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

Kuzmina, A., Khalaila, Y., Voloshin, O., Keren‐Naus, A., Cohen, L. B., Raviv, Y., Shemer‐Avni, Y., Rosenberg, E., & Taube, R. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.008 · Cited by 172 · see citing works

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

Rockett, R. J., Basile, K., Maddocks, S., Fong, W., Agius, J. E., Johnson-Mackinnon, J., Arnott, A., Chandra, S., Gall, M., Draper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2120219 · Cited by 171 · see citing works

SARS-CoV-2 evolution and vaccines: cause for concern?

Williams, T., & Burgers, W. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00075-8 · Cited by 163 · see citing works

Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development

Huang, X., Tang, T., Zhang, G., & Liang, T. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01342-6 · Cited by 155 · see citing works

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 152 · see citing works

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651 · see citing works

Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines

Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 148 · see citing works

Evolutionary trajectory of SARS-CoV-2 and emerging variants

Singh, J., Pandit, P., McArthur, A. G., Banerjee, A., & Mossman, K. L. (2021) · Virology Journal · doi:10.1186/s12985-021-01633-w · Cited by 144 · see citing works

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants

Tea, F., Stella, A. O., Aggarwal, A., Darley, D. R., Pilli, D., Vitale, D., Merheb, V., Lee, F. X. Z., Cunningham, P., Walker, G. J., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003656 · Cited by 134 · see citing works

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, M., Marco, A. D., Lempp, F., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · doi:10.1101/2021.01.14.426475 · Cited by 901 · see citing works

Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis

Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 116 · see citing works

Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination

Cobey, S. E., Larremore, D. B., Grad, Y. H., & Lipsitch, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00544-9 · Cited by 118 · see citing works

Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity

Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 112 · see citing works

Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677Preprint

Hodcroft, E. B., Domman, D., Snyder, D. J., Oguntuyo, K. Y., Diest, M. V., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.12.21251658 · Cited by 109 · see citing works

Parental nucleosome segregation and the inheritance of cellular identity

Escobar, T. M., Loyola, A., & Reinberg, D. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00312-w · Cited by 106 · see citing works

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

Jabłońska, K., Aballéa, S., & Toumi, M. (2021) · Public Health · doi:10.1016/j.puhe.2021.07.037 · Cited by 103 · see citing works

The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape

Tian, D., Sun, Y., Zhou, J., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27376 · Cited by 101 · see citing works

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variantPreprint

Edara, V. V., Lai, L., Sahoo, M. K., Floyd, K. A., Sibai, M., Solis, D., Flowers, M. W., Hussaini, L., Ciric, C. R., Bechnak, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.09.443299 · Cited by 100 · see citing works

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs

Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 85 · see citing works

Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display

Norman, A. R., Franck, C., Christie, M., Hawkins, P. M. E., Patel, K., Ashhurst, A. S., Aggarwal, A., Low, J. K. K., Siddiquee, R., Ashley, C. L., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01708 · Cited by 76 · see citing works

Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases

Chen, Z., Cui, Q., Cooper, L. M., Zhang, P., Lee, H., Chen, Z., Wang, Y., Liu, X., Rong, L., & Du, R. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00564-x · Cited by 73 · see citing works

Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations

Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00139 · Cited by 62 · see citing works

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J. S., Liu, Z., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 63 · see citing works

Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine

Zhong, H., Liu, S., Cao, F., Zhao, Y., Zhou, J., Tang, F. R., Peng, Z., Li, Y., Xu, S., Wang, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709986 · Cited by 72 · see citing works

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72 · see citing works

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55 · see citing works

One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages

Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 65 · see citing works

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Liu, H., Yuan, M., Huang, D.-L., Bangaru, S., Zhao, F.-Z., Lee, C. D., Peng, L., Barman, S., Zhu, X.-Y., Nemazee, D., et al. (2021) · Cell Host and Microbe · doi:10.1016/j.chom.2021.04.005 · Cited by 46 · see citing works

Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodiesPreprint

Tada, T., Dcosta, B. M., Zhou, H., Vaill, A., Kazmierski, W., & Landau, N. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.18.431897 · Cited by 59 · see citing works

Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines

Valdés-Balbín, Y., Santana-Mederos, D., Paquet, F., Fernández-Castillo, S., Climent, Y., Chiodo, F., Rodríguez, L., Ramírez, B. S., León, K., Hernández, T., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00216 · Cited by 53 · see citing works

Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’ variant

Fournier, P., Colson, P., Levasseur, A., Devaux, C. A., Gautret, P., Bedotto, M., Delerce, J., Bréchard, L., Pinault, L., Lagier, J., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.03.068 · Cited by 54 · see citing works

Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021

Wilton, T., Bujáki, E., Klapsa, D., Majumdar, M., Zambon, M. C. F. A., Fritzsche, M., Mate, R., & Martín, J. E.-S. (2021) · mSystems · doi:10.1128/msystems.00353-21 · Cited by 53 · see citing works

One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening

Francino-Urdaniz, I., Steiner, P. J., Kirby, M. B., Zhao, F.-Z., Haas, C. M., Barman, S., Rhodes, E. R., Leonard, A. C., Peng, L., Sprenger, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109627 · Cited by 31 · see citing works

On the road to ending the COVID-19 pandemic: Are we there yet?

Case, J., Winkler, E. S., Errico, J., & Diamond, M. S. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 41 · see citing works

SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity

Huang, S., & Wang, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063060 · Cited by 48 · see citing works

Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots

Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00372 · Cited by 40 · see citing works

CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., et al. (2021) · doi:10.1101/2021.03.22.435960 · Cited by 48 · see citing works

Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections

Ahmad, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742167 · Cited by 46 · see citing works

The Development of SARS-CoV-2 Variants: The Gene Makes the Disease

Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 45 · see citing works

ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2

Iwanaga, N., Cooper, L. M., Rong, L., Maness, N. J., Beddingfield, B. J., Qin, Z., Crabtree, J. M., Tripp, R. A., Yang, H., Blair, R. V., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103670 · Cited by 46 · see citing works

COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

Porta-Etessam, J., Nuñez-Gil, I. J., García, N. G., Fernández, C., Viana-Llamas, M. C., Maroun‐Eid, C., Romero, R., Molina, M., Uribarri, A., Becerra‐Muñoz, V. M., et al. (2021) · Infection · doi:10.1007/s15010-021-01587-9 · Cited by 42 · see citing works

Estimation of Secondary Household Attack Rates for Emergent Spike L452R Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Detected by Genomic Surveillance at a Community-Based Testing Site in San Francisco

Peng, J., Liu, J., Mann, S. A., Mitchell, A. M., Laurie, M. T., Sunshine, S., Pilarowski, G., Ayscue, P., Kistler, A., Vanaerschot, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab283 · Cited by 41 · see citing works

Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan

Hirotsu, Y., & Omata, M. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009619 · Cited by 39 · see citing works

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 34 · see citing works

Novel and emerging mutations of SARS-CoV-2: Biomedical implications

Mohammadi, E., Shafiee, F., Shahzamani, K., Ranjbar, M. M., Alibakhshi, A., Ahangarzadeh, S., Beikmohammadi, L., Shariati, L., Hooshmandi, S., Ataei, B., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111599 · Cited by 38 · see citing works

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

Lusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 33 · see citing works

Omicron: a drug developer’s perspective

Fang, F., & Shi, P. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2023330 · Cited by 34 · see citing works

Single domain shark VNAR antibodies neutralize SARS‐CoV‐2 infection in vitro

Gauhar, A., Privezentzev, C. V., Demydchuk, M., Gerlza, T., Rieger, J., Kungl, A. J., Walsh, F. S., Rutkowski, J. L., & Stocki, P. (2021) · The FASEB Journal · doi:10.1096/fj.202100986rr · Cited by 30 · see citing works

Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2 Marseille-4 variant

Bedotto, M., Fournier, P., Houhamdi, L., Levasseur, A., Delerce, J., Pinault, L., Padane, A., Chamieh, A., Tissot‐Dupont, H., Brouqui, P., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104814 · Cited by 27 · see citing works

The Emergence and Spread of Novel SARS-CoV-2 Variants

Yi, H., Wang, J., Wang, J., Lu, Y., Zhang, Y., Peng, R., Lu, J., & Chen, Z. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.696664 · Cited by 28 · see citing works

Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants

Liu, Z., Wu, H., Egland, K. A., Gilliland, T. C., Dunn, M. D., Luke, T. C., Sullivan, E. J., Klimstra, W. B., Bausch, C. L., & Whelan, S. P. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940652 · Cited by 26 · see citing works

The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes

Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 27 · see citing works

Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope

Makdasi, E., Levy, Y., Alcalay, R., Noy-Porat, T., Zahavy, E., Mechaly, A., Epstein, E., Peretz, E., Cohen, H., Bar-On, L., et al. (2021) · Viruses · doi:10.3390/v13040566 · Cited by 25 · see citing works

The challenge of emerging SARS-CoV-2 mutants to vaccine development

Li, R., Liu, J., & Zhang, H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.001 · Cited by 24 · see citing works

Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID‐19 vaccines in Europe

Wagner, R., Meißner, J., Grabski, E., Sun, Y., Vieths, S., & Hildt, E. (2021) · Allergy · doi:10.1111/all.14868 · Cited by 24 · see citing works

Biology of the SARS-CoV-2 Coronavirus

Mingaleeva, R. N., Nigmatulina, N. A., Sharafetdinova, L. M., Romozanova, A. M., Gabdoulkhakova, A. G., Викторовна, Ф. Ю., Фирнаялович, Ш. Р., Rizvanov, A. A., & Рифкатовна, М. Р. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922120215 · Cited by 24 · see citing works

A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants

Colson, P., Devaux, C. A., Lagier, J., Gautret, P., & Raoult, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153276 · Cited by 22 · see citing works

COVID‐19: emergence and mutational diversification of SARS‐CoV‐2

Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13800 · Cited by 23 · see citing works

SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1 lineage in Japan: Serial and stationary observation in a community

Hirotsu, Y., & Omata, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105088 · Cited by 20 · see citing works

SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies

Jeda, A. S., Abbassi, S., Mousavizadeh, A., Esghaie, M., Bokharaei‐Salim, F., Jeddi, F., Shafaati, M., & Abdoli, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108232 · Cited by 21 · see citing works

Fractionation of sulfated galactan from the red alga Botryocladia occidentalis separates its anticoagulant and anti-SARS-CoV-2 properties

Kim, S. B., Zoepfl, M., Samanta, P., Zhang, F., Xia, K., Thara, R., Linhardt, R. J., Doerksen, R. J., McVoy, M. A., & Pomin, V. H. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101856 · Cited by 20 · see citing works

Spread of endemic SARS-CoV-2 lineages in Russia before April 2021

Klink, G. V., Safina, K. R., Garushyants, S. K., Moldovan, M. A., Nabieva, E., Komissarov, A. B., Lioznov, D. A., & Bazykin, G. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270717 · Cited by 21 · see citing works

Clinical, virologic and immunologic features of a mild case of SARS-CoV-2 reinfection

Vetter, P., Cordey, S., Schibler, M., Vieux, L., Després, L., Laubscher, F., Andrey, D. O., Martischang, R., Harbarth, S., Cuvelier, C., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.02.010 · Cited by 18 · see citing works

COVID-19 Variants and Vaccine Development

Zhao, Z., Bashiri, S., Ziora, Z. M., Tóth, I., & Skwarczyński, M. (2024) · Viruses · doi:10.3390/v16050757 · Cited by 19 · see citing works

Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies

Velázquez‐Moctezuma, R., Augestad, E. H., Castelli, M., Olesen, C. H., Clementi, N., Clementi, M., Mancini, N., & Prentoe, J. C. (2021) · Vaccines · doi:10.3390/vaccines9030291 · Cited by 18 · see citing works

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

Makdasi, E., Zvi, A., Alcalay, R., Noy-Porat, T., Peretz, E., Mechaly, A., Levy, Y., Epstein, E., Chitlaru, T., Tennenhouse, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109679 · Cited by 19 · see citing works

Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovinesPreprint

Gilliland, T. H., Liu, Y., Li, R., Dunn, M., Cottle, E. L., Terada, Y., Ryckman, Z., Alcorn, M. D. H., Vasilatos, S. N., Lundy, J. D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.26.453840 · Cited by 18 · see citing works

Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individualPreprint

Williamson, M. K., Hamilton, F., Hutchings, S., Pymont, H. M., Hackett, M., Arnold, D., Maskell, N. A., MacGowan, A. P., Albur, M., Jenkins, M. H., et al. (2021) · medRxiv · doi:10.1101/2021.05.31.21257591 · Cited by 17 · see citing works

Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination

Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 16 · see citing works

Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential

Kubik, S., Arrigo, N., Bonet, J., & Xu, Z. (2021) · Viruses · doi:10.3390/v13112114 · Cited by 16 · see citing works

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants

Liu, J., Chen, Q., Yang, S., Li, Y., Dou, Y., Deng, Y., Bi, J., Tan, Y., Hongfan, W., Gong, W., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00293-y · Cited by 14 · see citing works

Variantes del SARS-CoV-2: epidemiología, fisiopatología y la importancia de las vacunas

Bedoya-Sommerkamp, M., Medina-Ranilla, J., Rodriguez, V. H. C., Li-Soldevilla, R., Vera-Albújar, Á., & Garcia, P. J. (2021) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2021.383.8734 · Cited by 13 · see citing works

Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study

Cheon, S., Park, U., Park, H., Kim, Y., Yến, N. T. H., Aigerim, A., Rhee, J.-Y., Choi, J., Park, W. B., Park, S., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.009 · Cited by 13 · see citing works

A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis

McLaughlin, K.-M., Bojková, D., Kandler, J. D., Bechtel, M., Reus, P., Le, T. T., Rothweiler, F., Wagner, J. U. G., Weigert, A., Ciesek, S., et al. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43030086 · Cited by 12 · see citing works

Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency

Mariotti, S., Capocefalo, A., Chiantore, M. V., Iacobino, A., Teloni, R., Angelis, M. L. D., Gallinaro, A., Pirillo, M. F., Borghi, M., Canitano, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750386 · Cited by 13 · see citing works

Structural basis of fitness of emerging SARS-COV-2 variants and considerations for screening, testing and surveillance strategy to contain their threatPreprint

Islam, S. R., Prusty, D., & Manna, S. K. (2021) · medRxiv · doi:10.1101/2021.01.28.21250666 · Cited by 13 · see citing works

Exploring COVID-19 vaccine hesitancy and behavioral themes using social media big-data: a text mining approach

Yadav, H., & Sagar, M. (2023) · Kybernetes · doi:10.1108/k-06-2022-0810 · Cited by 12 · see citing works

Evidence of SARS-CoV-2 symptomatic reinfection in four healthcare professionals from the same hospital despite the presence of antibodies

Gargouri, S., Souissi, A., Abid, N., Chtourou, A., Fki‐Berrajah, L., Karray, R., Kossentini, H., Ayed, I. B., Abdelmoula, F., Chakroun-Walha, O., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.006 · Cited by 12 · see citing works

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725 · see citing works

Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD

Peter, A. S., Grüner, E., Socher, E., Fraedrich, K., Richel, E., Mueller-Schmucker, S. M., Cordsmeier, A., Ensser, A., Sticht, H., & Überla, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158177 · Cited by 12 · see citing works

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308 · see citing works

SARS‐CoV ‐2 neutralizing antibody epitopes are overlapping and highly mutated which raises the chances of escape variants and requires development of broadly reactive vaccines

Joseph, J., Darpe, S., Kulkarni, G., & Raj, V. S. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26488 · Cited by 2 · see citing works

Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants

Mittal, A., Khattri, A., & Verma, V. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010260 · Cited by 121 · see citing works